Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Feb 16, 2021

SEC Form 4/A — Form 4/A

Issuer: Lineage Cell Therapeutics, Inc. (LCTX)
CIK: 0000876343
Period of Report: 2016-07-01

Reporting Person: BRADSHER NEAL C (Director, 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
OPTION TO PURCHASE COMMON SHARES	$1.67	2023-06-30	COMMON SHARES (49440)	49440	Direct
OPTION TO PURCHASE COMMON SHARES	$2.55	2022-06-30	COMMON SHARES (24720)	24720	Direct
OPTION TO PURCHASE COMMON SHARES	$2.20	2021-06-30	COMMON SHARES (24720)	24720	Direct

Footnotes

F1: This amendment to the Form 4 filed by Neal C. Bradsher on July 2, 2020 (the "July 2020 Form 4") is being made solely to correct the exercise price of certain options to purchase common shares of Lineage Cell Therapeutics, Inc. (the "Issuer") currently held by Mr. Bradsher (collectively, the "Stock Options"). In particular, the respective exercise prices of these reported Stock Options were adjusted following the distribution of shares of common stock of AgeX Therapeutics, Inc. to the Issuer's shareholders on November 28, 2018 (the "AgeX Distribution"). The number of Stock Options was properly adjusted at the time of the AgeX Distribution; however, the exercise prices of these reported Stock Options were not properly adjusted. For the avoidance of doubt, none of the Stock Options reported in this Form 4 amendment or the July 2020 Form 4 filing have been exercised.

F2: These options are currently exercisable.